Application Detail
Status
ClosedDescription of Medical Service
This is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.Description of Medical Condition
Outside Australia, this test is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.Reason for Application
New MBS itemMedical Service Type
InvestigativePrevious Application Number
Not ApplicableAssociated Documentation
Application Form
-PICO Confirmation
No second PASC requiredFinal Protocol (PDF 1158 KB)
Final Protocol (Word 488 KB)
Assessment Report
-Public Summary Document
Final Public Summary Document (PDF 240 KB)Final Public Summary Document (Word 138 KB)